Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quanterix Corporation (NASDAQ: QTRX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI‑supported context to help interpret them. As a life sciences and testing laboratories company focused on ultra-sensitive biomarker detection and spatial biology, Quanterix uses its SEC reports to describe its financial performance, corporate transactions, and governance decisions.
Key documents available here include Form 10‑K annual reports and Form 10‑Q quarterly reports, which outline revenue from product sales, service and other revenue, collaboration and license revenue, and grant revenue. These filings also discuss cost of goods sold, research and development expenses, selling, general and administrative expenses, and the use of non‑GAAP measures such as adjusted EBITDA, adjusted gross margin, and adjusted cash usage. AI summaries can highlight how these metrics relate to Quanterix’s Simoa platforms, Accelerator Laboratory services, and the integration of Akoya Biosciences.
Frequent Form 8‑K current reports document material events. Recent examples include announcements of quarterly financial results, the completion and pro forma impact of the Akoya acquisition, shareholder votes on declassifying the Board and eliminating supermajority voting requirements, and changes in Board composition. Our tools surface the main points of each 8‑K so readers can quickly understand what changed and why it matters for QTRX.
Investors can also review proxy statements referenced in the filings for details on director elections, executive compensation proposals, and governance changes, as well as any Form 4 insider transaction reports that may be filed separately. Real‑time updates from EDGAR ensure that new filings appear promptly, while AI‑generated explanations help translate technical accounting and legal language into more accessible summaries.
Use this page to explore Quanterix’s historical and current SEC filings, compare reporting periods, and understand how financial results, acquisitions, and governance actions are reflected in official disclosures.
Quanterix Corp (QTRX)November 20, 2025, the director acquired 46,727 shares of common stock through a grant of restricted stock units (RSUs), reported as an acquisition in a Form 4 filing. Following this grant, the director beneficially owns 46,727 shares directly.
The RSUs vest in three equal installments. One-third of the total shares vest on each of November 20, 2026, November 20, 2027 and November 20, 2028, provided the director continues to provide service to Quanterix on each vesting date. This filing reflects routine director equity compensation rather than an open‑market purchase or sale.
Quanterix Corporation (QTRX)70,091 shares of Quanterix common stock at an exercise price of $5.91 per share. These options expire on 11/20/2035.
The options vest monthly over two years in 24 equal installments, as long as the Executive Chair continues providing service to Quanterix on each vesting date. Following this transaction, the reporting person beneficially owns 70,091 derivative securities directly.
Quanterix Corporation’s Chief Financial Officer reported a routine equity transaction on Form 4. On 11/15/2025, 229 shares of common stock were withheld by Quanterix solely to cover tax obligations when 777 restricted stock units vested. After this tax withholding, the reporting person beneficially owns 86,206 shares of Quanterix common stock, which includes 85,429 restricted stock units that may convert into shares over time.
Quanterix Corp (QTRX) reported an insider equity transaction by its President & CEO, who is also a director. On 11/15/2025, 1,242 shares of common stock were withheld under transaction code "F", meaning the shares were retained by the company solely to cover tax obligations triggered by the vesting of 2,480 restricted stock units (RSUs). Following this tax withholding, the reporting person beneficially owns 510,200 shares of Quanterix common stock, which includes 216,606 RSUs.
Quanterix Corporation reported changes to its Board of Directors. Long-time directors Paul Meister and David Walt, Ph.D. retired from the Board and all its committees, and their departures were stated as not arising from any disagreement with the company’s operations, policies, or practices.
The Board appointed Garret Hampton, Ph.D., as a Class II director with a term expiring at the 2028 annual meeting, and Alan Sachs, M.D., Ph.D., as a Class I director with a term expiring at the 2027 annual meeting. Dr. Hampton will serve on the Audit and Compensation Committees, while Dr. Sachs will serve on the Compensation Committee.
Both new directors will receive an annual cash retainer of $50,000 plus additional committee retainers. Each will receive an initial restricted stock unit grant equal to 0.1% of Quanterix’s outstanding common shares on the grant date, vesting over three years, and ongoing annual RSU grants equal to 0.05% of outstanding shares, vesting after one year.
Quanterix Corporation (QTRX) reported Q3 2025 results with total revenues of $40.2 million, up from $35.8 million a year ago, driven by stronger product revenue of $26.2 million versus $19.7 million. Service and other revenue was $14.0 million, roughly flat year over year. Gross profit was $17.2 million compared with $20.2 million, as costs rose with the expanding business.
The company recorded a net loss of $33.5 million (vs. $8.4 million), reflecting higher selling, general and administrative expenses of $39.1 million, $7.2 million of impairment and restructuring costs, and $5.2 million of Akoya acquisition-related costs. Year-to-date operating cash flow used was $60.8 million. Cash and cash equivalents were $38.3 million and marketable securities $96.5 million at September 30, 2025.
Quanterix closed the Akoya Biosciences acquisition on July 8, 2025, with total consideration of $151.0 million, including $49.2 million in stock, $18.9 million in cash to shareholders, $82.1 million to extinguish debt, and recognized $121.8 million of acquired intangible assets and $23.5 million of goodwill. The quarter included $1.2 million of non-cash revenue from amortizing an acquired off‑market contract liability.
Quanterix Corporation (QTRX) furnished an Item 2.02 update announcing financial results for the third quarter ended September 30, 2025. The company provided an earnings press release and accompanying presentation slides as exhibits. The information in this item, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act.
Exhibits include: 99.1 Earnings Release (November 10, 2025) and 99.2 Earnings Call Slides. The report was signed by Chief Financial Officer Vandana Sriram.
Quanterix (QTRX) reported an insider tax-withholding event by its President & CEO and Director. On October 31, 2025, 254 shares of common stock were withheld at $5.34 to cover taxes upon vesting of 761 RSUs.
After this transaction, the insider beneficially owns 511,442 shares, which includes 219,086 RSUs. The filing reflects routine administration of equity compensation rather than an open‑market sale.
Quanterix (QTRX) insider update: The Chief Financial Officer reported a tax-withholding transaction on 10/15/2025. Code F indicates 229 shares of common stock were withheld at $5.78 per share to satisfy taxes upon vesting of 777 restricted stock units.
Following this non‑open‑market event, the officer beneficially owns 86,742 shares, which includes 70,893 RSUs.
Quanterix Corp (QTRX) disclosed an insider transaction by its President & CEO and Director on 10/15/2025. The filing shows 1,242 shares of common stock were withheld (code F) at $5.78 per share to cover taxes upon the vesting of 3,722 RSUs.
Following this tax-withholding transaction, the reporting person beneficially owns 511,696 shares, which includes 219,847 RSUs. This is an administrative, non‑open market event tied to equity award vesting.
FAQ
What is the current stock price of Quanterix (QTRX)?
What is the market cap of Quanterix (QTRX)?
